| __timestamp | Agios Pharmaceuticals, Inc. | ImmunityBio, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 1595000 |
| Thursday, January 1, 2015 | 141827000 | 11434000 |
| Friday, January 1, 2016 | 220163000 | 26546000 |
| Sunday, January 1, 2017 | 292681000 | 39778000 |
| Monday, January 1, 2018 | 341324000 | 53418000 |
| Tuesday, January 1, 2019 | 410894000 | 111997000 |
| Wednesday, January 1, 2020 | 367470000 | 139507000 |
| Friday, January 1, 2021 | 256973000 | 195958000 |
| Saturday, January 1, 2022 | 279910000 | 248149000 |
| Sunday, January 1, 2023 | 288903000 | 232366000 |
| Monday, January 1, 2024 | 301286000 |
Data in motion
In the ever-evolving world of biotechnology, research and development (R&D) is the lifeblood of innovation. Over the past decade, Agios Pharmaceuticals, Inc. and ImmunityBio, Inc. have been at the forefront of this transformative journey.
Agios Pharmaceuticals has consistently invested in R&D, with expenses peaking in 2019, marking a 310% increase from 2014. This commitment underscores their dedication to pioneering therapies in oncology and rare genetic diseases. Meanwhile, ImmunityBio, Inc. has shown a remarkable growth trajectory, with R&D expenses surging by over 14,500% from 2014 to 2022. This exponential rise highlights their aggressive pursuit of novel immunotherapy solutions.
As we look to the future, these trends not only reflect the companies' strategic priorities but also signal the broader industry's shift towards innovative, life-saving treatments. The data paints a compelling picture of how strategic R&D investments can drive breakthroughs in healthcare.
Comparing Innovation Spending: Johnson & Johnson and ImmunityBio, Inc.
Incyte Corporation vs Agios Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
R&D Insights: How Halozyme Therapeutics, Inc. and ImmunityBio, Inc. Allocate Funds
R&D Insights: How Lantheus Holdings, Inc. and ImmunityBio, Inc. Allocate Funds
R&D Spending Showdown: Madrigal Pharmaceuticals, Inc. vs Agios Pharmaceuticals, Inc.
R&D Spending Showdown: Axsome Therapeutics, Inc. vs Agios Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Amneal Pharmaceuticals, Inc. and ImmunityBio, Inc.
Perrigo Company plc or ImmunityBio, Inc.: Who Invests More in Innovation?
R&D Spending Showdown: MorphoSys AG vs Agios Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for ImmunityBio, Inc. and Celldex Therapeutics, Inc.
Soleno Therapeutics, Inc. vs Agios Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
R&D Insights: How Agios Pharmaceuticals, Inc. and Wave Life Sciences Ltd. Allocate Funds